Skip to main content
Premium Trial:

Request an Annual Quote

LSBC, U. of Arkansas for Medical Sciences to Produce Drug Abuse Antibody Treatment

NEW YORK, Feb. 28 -Large Scale Biology and the University of Arkansas for Medical Sciences in Little Rock, Ark., have announced an agreement to manufacture therapeutic antibodies to drugs of abuse, the company said today.

 

Under the agreement, LSBC will first produce an antibody target for the street drug phencyclidine, also known as "angel dust" and PCP.

 

Michael Owens, who is the director of UAMS; center for alcohol and drug abuse studies, chose LSBC for the production of the antibody. The contract will be financed by National Institute on Drug Abuse grants that fund Owens' research. Owens group has demonstrated through preclinical studies on animals that a monoclonal antibody has potential use for PCP abusers, according to LSBC.

 

For more information, see the company statement.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.